Targeting FcRn to Generate Antibody-Based Therapeutics.

Ward, E Sally; Ober, Raimund J

Ward, E Sally; Ober, Raimund J.

Afiliación

Ward ES; Department of Molecular and Cellular Medicine, College of Medicine, Texas A&M University Health Science Center, College Station, TX 77843, USA; Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M University Health Science Center, Bryan, TX 77807, USA; Cancer Sciences Unit, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK. Electronic address: sally.ward@tamu.edu.
Ober RJ; Department of Molecular and Cellular Medicine, College of Medicine, Texas A&M University Health Science Center, College Station, TX 77843, USA; Cancer Sciences Unit, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK; Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA.

Trends Pharmacol Sci ; 39(10): 892-904, 2018 10.

Article en En | MEDLINE | ID: mdl-30143244

Asunto(s)

Antígenos de Histocompatibilidad Clase I; Inmunoglobulina G; Receptores Fc; Animales; Complejo Antígeno-Anticuerpo; Humanos; Transporte de Proteínas

Palabras clave

FcRn; FcRn-targeted therapeutics; antibody engineering; pharmacokinetics

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoglobulina G / Receptores Fc / Antígenos de Histocompatibilidad Clase I Límite: Animals / Humans Idioma: En Revista: Trends Pharmacol Sci Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google